Emerging Business Models in the Pharmaceutical Industries ...

Rank
6
7
8
9
10
SWOT Analysis of Top 10 Pharma Companies
Company
Merck & Co
AstraZeneca
Wyeth
Eli Lily & Co
Bristol Myers
Squibb
Source: JSB Intelligence
Strengths Weaknesses Opportunity Threats
Strong product pipeline,
work redesign initiatives
Strong geographic
presence
Strong brand
recognition, patent
protected drugs, variety
of OTC analgesic and
hygiene products
Specialisation in
neurosciences, good US
market share
Major alliances and
acquisitions, growth of
new products
Poor presence in
growing Europe and
Asia. Cost
escalations and
increased
development time
Limited last stage
pipeline, delay in
new product
launches
High debt obligations
because of M&A,,
disinvestments in
stable money
makers
High dependence on
block busters drugs
Mature product
portfolio, lack of
growth potential in
late stage pipeline
External scientific
research alliances,
potential market in
developing countries
Growth prospects
within the
cardiovascular
franchise field
Ageing population,
consumers taking
active participation in
health care, strong
drug pipeline providing
blockbuster drugs in
future, advances in
genomic technology,
molecular biology
Foraying into
Japanese market,
controlled diabetics
services
Potential in HIV
market, opportunity in
M&A
Pulling of Vioxx has created
a major void in revenue
model for Merck. No
immediate replacement by
newer drug can lead to
potential reduction in
revenues.
Currency fluctuations,
expiry of patents
Changing regulatory
environment, competition
from generic products,
pressure from state
legislations and third party
payers, inadequate
intellectual property
protection
Competition, regulatory
approval, decrease in R&D
productivity
Loss of patent protection,
legal proceedings, pressure
on R&D activities
Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players 55